Xortx Therapeutics inc (XRTX) - News Archive

Title : XORTX Therapeutics Begins IND Preparation for XORLO in Gout Program Amid Market FluctuationsIn a strategic move that could lead to significant advances in gout treatment, XORTX Therapeutics Inc. (NASDAQ: XRTX) h...

Accelerating Pathways: XORTX’s Strategic Developments in Gout Treatment In recent developments within the biotechnology sector, XORTX Therapeutics Inc. has captured attention with its ongoing strides towards advancing i...

XORTX Therapeutics Inc. Announces Change of Auditor Amid Financial Turbulence and Leadership ShakeupCALGARY, Alberta – XORTX Therapeutics Inc. (XORTX or the Company) has taken a significant step as part of its strategic...

XORTX Therapeutics Faces Financial Headwinds as it Shifts Focus on Gout Treatment Amid Leadership ChangesIn an era marked by relentless innovation in biopharmaceuticals, XORTX Therapeutics Inc. appears to be navigating...

XORTX Therapeutics Inc. has announced a significant addition to its executive team with the appointment of Dr. Michael Bumby as Chief Financial Officer (CFO). Dr. Bumby s expertise in the pharmaceutical and biotechnolog...

XORTX Secures $1.5 Million Funding to Propel Innovative Kidney Disease TherapiesCALGARY, Alberta On October 18, 2024, XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU) announced the successful closing...

In a significant stride towards pioneering advancements in kidney disease therapy, XORTX Therapeutics Inc. (XORTX or the Company) has announced the initiation of its Precision Medicine Program. This program leverages in...

XORTX Reminds Shareholders of Voting Deadline for Upcoming Annual and Special Meeting of ShareholdersCALGARY, Alberta, Sept. 06, 2024 - XORTX Therapeutics Inc. (XORTX or the Company) (NASDAQ: XRTX | TSXV: XRTX | Frankfu...

XORTX Therapeutics Unveils Groundbreaking Research Linking Genetic Regulation of Xanthine Oxidase to Chronic Kidney Disease: A Potential Paradigm Shift in Therapeutic Approaches In a significant advancement that could r...

Calgary-based late-stage clinical pharmaceutical company, XORTX Therapeutics Inc., has recently announced receiving approval from the TSX Venture Exchange (TSXV) for amending the terms of its outstanding common share pu...

XORTX Therapeutics Inc. Announces Significant Research Findings in ADPKDCalgary, Alberta, April 22, 2024 - XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a leading late-stage clinical...

XORTX Therapeutics Inc.: A Promising Future for Progressive Kidney Disease TreatmentXORTX Therapeutics Inc. (XORTX), a leading clinical pharmaceutical company, has achieved significant milestones in 2023 and is poised t...

XORTX Finalizes $2.7 Million Fundraising Strategy Amidst Growing DemandIn a move aimed at capitalizing on the increasing demand for its innovative offerings, XORTX Therapeutics Inc. has recently concluded a successful f...

In a recent press release, Xortx Therapeutics Inc, a prominent player in the industry, reported its Quick Ratio ranking for the fourth quarter of 2021. While the company has managed to maintain a fairly stable position,...

CALGARY, Alberta, Nov. 10, 2023 - XORTX Therapeutics Inc. (XORTX) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a leading clinical pharmaceutical company focusing on groundbreaking therapies for progressive kidney disea...

XORTX Announces Share Consolidation: A Strategic Move Towards ProgressBy CALGARY, Alberta, Nov. 08, 2023 - XORTX Therapeutics Inc. (XORTX or the Company) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinic...